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MaBACKGROUND Leucocyte telomere length (LTL) shortening is associated with cardiovascular ischemic events and
mortality in humans, but data on its association with subclinical atherosclerosis are scarce. Whether the incidence and
severity of subclinical atherosclerosis are associated with the abundance of critically short telomeres, a major trigger of
cellular senescence, remains unknown.
OBJECTIVES The authors conducted a cross-sectional exploration of the association between subclinical
atherosclerosis burden and both average LTL and the abundance of short telomeres (%LTL<3 kb).
METHODS Telomere length was assessed by high-throughput quantitative ﬂuorescence in situ hybridization in circu-
lating leukocytes from 1,459 volunteers without established cardiovascular disease (58% men, 40 to 54 years of age)
from the PESA (Progression of Early Subclinical Atherosclerosis) study. Subclinical atherosclerosis was evaluated by
coronary artery calcium scan and 2-dimensional/3-dimensional ultrasound in different aortic territories. Statistical sig-
niﬁcance of differences among multiple covariates was assessed with linear regression models. Independent associations
of telomere parameters with plaque presence were evaluated using general linear models.
RESULTS In men and women, age was inversely associated with LTL (Pearson’s r ¼ 0.127, p < 0.001) and directly
with %LTL<3 kb (Pearson’s r ¼ 0.085; p ¼ 0.001). Short LTL reached statistical signiﬁcance as a determinant of
total and femoral plaque in men, but not in women. However, this association was not sustained after adjustment for age
or additional adjustment for cardiovascular risk factors. No signiﬁcant independent association was found between
%LTL<3 kb and plaque burden. Serum-oxidized low-density lipoprotein levels were directly associated with %LTL<3 kb
in men (p ¼ 0.008) and women (p < 0.001).
CONCLUSIONS In a cross-sectional study of a middle-aged population, average LTL and short telomere load are not
signiﬁcant independent determinants of subclinical atherosclerosis. Longitudinal follow-up of PESA participants will
assess long-term associations between telomere length and progression of subclinical atherosclerosis.
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ABBR EV I A T I ON S
AND ACRONYMS
%LTL<3 kb = percent short
telomeres (<3 kb)
2D = 2-dimensional
3D = 3-dimensional
CACS = coronary artery
calcium score
CT = computed tomography
CVD = cardiovascular disease
DNA = deoxyribonucleic acid
HT-QFISH = high-throughput
quantitative ﬂuorescence in
situ hybridization
IMT = intima-media thickness
LTL = leucocyte telomere
length
ox-LDL = oxidized low-density
lipoprotein
TL = telomere length
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2468A therosclerosis and associated myo-cardial infarction or stroke are themajor cause of morbidity and mor-
tality in industrialized countries, and the
economic, social, and human costs associ-
ated with treating cardiovascular disease
(CVD) are painfully high (1). Our previous re-
sults revealed highly prevalent subclinical
atherosclerosis in almost one-half of 4,066
participants in the PESA (Progression of Early
Subclinical Atherosclerosis) study, all of
whom were free from established CVD; more-
over, noninvasive imaging demonstrated
frequent atherosclerosis in subjects at low
risk according to traditional risk scores (2).
To improve diagnosis and prevention, it is
thus urgent to reﬁne classic CVD risk scores
and identify new biomarkers of atheroscle-
rotic disease initiation and early progression.SEE PAGE 2477Attrition of telomeric DNA is assumed to be a
biomarker of aging and health status (3). Because age
is a crucial determinant of CVD (4), the possibility that
telomere attrition might predict cardiovascular risk
has awakened tremendous interest. Telomeres are
capping deoxyribonucleic acid (DNA)–nucleoprotein
complexes that protect the ends of all eukaryotic
chromosomes from degradation, unwanted recombi-
nation, or fusion (5). In most somatic cells, including
leukocytes, telomeric DNA is shortened with every cell
division throughout life from right after birth, in part
due to inactivation of the telomere-elongating poly-
merase telomerase. When telomeric DNA becomes
critically short, cells trigger an irreversible DNA dam-
age response that leads to cellular senescence and,
eventually, to apoptosis, thus compromising tissue
repair capacity and function (6). Although human
leukocyte telomere length (LTL) is predominantly
determined by inheritance, it can be inﬂuenced by
stresses during pregnancy and exhibits high interin-
dividual variability at the same age (7,8). Telomeric
dysfunction and attrition can be caused by genetic
mutations (9) or cardiovascular risk factors (e.g.,
inﬂammation, oxidative stress, lack of estrogens,
insulin resistance, smoking, obesity, alcohol abuse,
sedentary life-style, psychological stress) (10–12).
Numerous epidemiological studies have investi-
gated the relation between LTL and cardiovascular
ischemic events, but the outcomes are often con-
ﬂicting or too heterogeneous, as recently revealed in
2 independent meta-analyses (13,14). In their meta-
analysis of 27 studies, D’Mello et al. (13) found a sig-
niﬁcant association between shortened LTL andmyocardial infarction, type 2 diabetes mellitus, and
stroke. In their meta-analysis of 24 studies, many
overlapping those of D’Mello et al. (13), Haycock et al.
(14) also showed an inverse association between LTL
and nonfatal myocardial infarction, coronary heart
disease death, and coronary revascularization, but
the association with cerebrovascular disease was less
certain. Paradoxically, D’Mello et al. (13) did not ﬁnd a
signiﬁcant association between LTL and coronary
artery disease (a secondary outcome deﬁned as
angina and nonfatal ischemic heart disease), sug-
gesting that LTL attrition is a marker of plaque
rupture and associated ischemic events.
An interesting question is whether shortened LTL is
a prognostic biomarker for the early identiﬁcation of
subjects at high risk of developing CVD before symp-
toms appear. Compared with the wealth of informa-
tion available on short LTL and established CVD (e.g.,
myocardial infarction or stroke), few epidemiological
studies have focused on possible associations between
telomere length (TL) and subclinical (asymptomatic)
atherosclerosis. The Asklepios cohort study is the
largest reported to date (2,509 volunteers free from
established CVD, approximately 35 to 55 years of age)
(15). The main conclusion of the Asklepios study was
that shortened LTL is not a substantial determinant of
preclinical atherosclerosis in either sex, and that
the association between LTL and CVD cannot be
explained by increased predisposition to atheroscle-
rosis as a consequence of shorter inherited telomeres
(15). Atherosclerosis in the Asklepios study was
assessed in carotid and femoral arteries by intima-
media thickness (IMT) and by vascular echography
(absence/presence of plaque), but the potential asso-
ciation between LTL and plaque volume was not
assessed. Moreover, to the best of our knowledge, the
possible association between CVD and short telomere
load has not yet been investigated, despite ﬁrm evi-
dence showing that the accumulation of a few criti-
cally short telomeres in a cell can trigger cellular
senescence (16–20). Here, we performed a cross-
sectional study using high-throughput quantitative
ﬂuorescence in situ hybridization (HT-QFISH)
(18) to quantify the percentage of short telomeres
(%LTL <3 kb) and average LTL in a subset of 1,459
healthy volunteers in the PESA cohort, and investi-
gated the possible association of these parameters
with plaque burden measured by 3-dimensional (3D)
sonography in different vascular territories.
METHODS
STUDY DESIGN AND POPULATION. The PESA study
rationale and design were described elsewhere (21).
TABLE 1 Plaque Presence and Total Plaque Burden
Men
(n ¼ 848)
Women
(n ¼ 611)
Chi-Square
p Value
CASC $1 203 (24) 25 (4) <0.001
Carotid artery plaque 265 (31) 135 (22) <0.001
Iliofemoral artery plaque 417 (49) 141 (23) <0.001
Infrarenal aorta plaque 189 (23) 110 (18) 0.039
Men
(n ¼ 416)
Women
(n ¼ 158)
Student
t-Test
p Value
Total plaque burden
>0 (mm3)
Tertile 1 16.2  8.6 9.3  4.2 <0.001
Tertile 2 61.2  19.3 26.9  7.4 <0.001
Tertile 3 263.5  210.3 121.5  100.4 <0.001
Values are n (%) or mean  SD.
CASC ¼ coronary artery calcium score.
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2469In brief, PESA-CNIC-Santander is a prospective cohort
study including 4,066 asymptomatic employees at the
Banco de Santander Headquarters in Madrid (Spain).
Participants were 40 to 54 years of age at recruitment
(between June 2010 and February 2014) and were free
of established CVD. Peripheral blood samples suitable
for HT-QFISH (see the “Telomere Measurements in
Leukocytes” section) were available only from the last
1,500 participants recruited to the PESA study. Of
these, complete data were available for 1,459, who
were therefore included in the present study. This
subgroup shares similar main characteristics with the
overall PESA study cohort (e.g., sex, age) and exhibi-
ted slightly lower subclinical atherosclerosis preva-
lence (3% to 7% lower). Employees were invited to
participate during their regular annual medical
checkup by the company’s medical services. Subjects
with established CVD or any other condition reducing
life expectancy were excluded from the study. The
study visits include a clinical interview, physical ex-
amination (anthropometric measures, blood pressure,
and heart rate), a fasting blood draw and urine sample,
life-style questionnaires, accelerometry assessment of
physical activity, electrocardiogram, and assessment
of subclinical atherosclerosis by noninvasive vascular
imaging tests, including 2-dimensional (2D)/3D
vascular ultrasound and computed tomography (CT)
for coronary artery calcium score (CACS) measure-
ment. The ethics committee of Instituto de Salud
Carlos III in Madrid, Spain, approved the study pro-
tocol, and written informed consent was obtained
from each participant before enrollment.
LIFE-STYLE AND CVD RISK FACTORS. Traditional
risk factors, such as smoking habits and a diagnosis
of hypertension, diabetes, or dyslipidemia, were
collected as part of each participant’s medical history.
Blood pressurewasmeasured at rest with an automatic
oscillometric sphygmomanometer (OMRON HEM-907,
OMRON Healthcare, Kyoto, Japan). Anthropometric
measures were obtained following a standardized
procedure. Body mass index was calculated as body
mass divided by the squared height (kg/m2). Fasting
blood and urine samples were collected after z8 h of
fasting and tested for serum glucose, triglycerides,
total cholesterol, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, C-reactive pro-
tein, whole-blood glycosylated hemoglobin (HbA1c),
and markers of inﬂammation, such as oxidized
low-density lipoprotein (ox-LDL) and urinary
isoprostanes. Dietary intake was assessed with a
computerized questionnaire (Dietary History-Enrica),
conducted by trained dieticians, designed to record
habitual food intake over the previous year.VASCULAR ULTRASOUND. All ultrasound recordings
were analyzed at the PESA Core Imaging Labora-
tory at the CNIC. Imaging studies included vascular
2D ultrasound of carotid arteries, infrarenal aorta,
and iliofemoral arteries; 3D ultrasound of carotid and
femoral arteries; and CACS by CT scan. Vascular
ultrasound was performed with a Philips iU22 ultra-
sound station (Philips Healthcare, Bothell, Washing-
ton), with adapted scanning protocols (22). A 2D
high-resolution linear array transducer was used to
assess the presence of plaques, and a 3D
high-resolution transducer was used to assess
plaque volume and, subsequently, to estimate the
total atherosclerotic burden. Plaque burden was
quantiﬁed with a semiautomatic 3D plaque analysis
system engineered by Philips (Xcelera system and
QLAB-VPQ [vascular plaque quantiﬁcation]). Plaques
were deﬁned as any focal protrusion of more than
0.5 mm or more than 50% thicker than the sur-
rounding intima-media (23). The QLAB-VPQ system
estimated plaque burden by summing plaque areas
and plaque volumes from successive cross-sectional
scans of vascular segments containing atheroscle-
rotic lesions. CACS was estimated by noncontrast
electrocardiographic-gated prospective acquisition
with a 16-slice Brilliance CT scanner (Philips Health-
care, Andover, Massachusetts).
TELOMERE MEASUREMENTS IN LEUKOCYTES. Peri-
pheral blood leukocytes were isolated with Histo-
paque (Sigma-Aldrich, St. Louis, Missouri), and cells
were frozen in freshly prepared 90% FBS-10% DMSO
and stored in liquid nitrogen until use. HT-QFISH in
96-well-plate format was performed on interphase
nuclei of leukocytes to determine mean LTL and
%LTL<3 kb (24). This technique uses high-throughput
FIGURE 1 Telomere Length in Circulating Leukocytes of Middle-Age Subjects Free From Established Cardiovascular Disease
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(A) Scatterplot of mean LTL (kb) against age for men and women. (B) Scatterplot of %LTL<3 kb against age for men and women.
(C) Scatterplot of %LTL<3 kb against mean LTL (kb) for men and women (cubic regression lines). N ¼ 848 men; N ¼ 611 women;
%LTL<3 kb ¼ percent short telomeres; LTL ¼ leukocyte telomere length.
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2470confocal microscopy to detect telomeres labeled with
a ﬂuorescent peptide nucleic acid probe against telo-
meric repeats. All samples were measured in dupli-
cate, and mean LTL and %LTL<3 kb were calculated
for each sample. Previous studies have used <3 kb as
the cutoff for “short telomeres” in humans (18,25).
The intra-assay coefﬁcient of variation was 6.3%
for LTL and 10.5% for %LTL<3 kb. For 152 randomly
chosen samples, duplicate measurements wererepeated in a different plate to calculate the inter-
assay coefﬁcient of variation, which was 5.6% for LTL
and 12.8% for %LTL<3 kb. The sample size (1,459) was
sufﬁcient to detect a standardized difference of 0.171
in LTL between groups with and without plaque with
a statistical power of 0.9.
STATISTICAL ANALYSIS. All statistical analyses were
performed using the Statistical Package for the Social
Sciences (version 20.0, SPSS, IBM Corp., Armonk,
TABLE 2 Baseline Characteristics Stratiﬁed by Sex and Total Plaque Burden
Men
Plaque Burden (mm3)*
Test for
Trend
p Value
No Plaque
(n ¼ 391)
Tertile 1†
(n ¼ 137)
Tertile 2†
(n ¼ 138)
Tertile 3†
(n ¼ 141)
Age, yrs 44.7  0.2 46.0  0.4 46.9  0.4 49.1  0.4 <0.001
LTL (kb) 10.17  0.09 9.74  0.17 9.71  0.15 9.94  0.15 0.033
%LTL<3 kb 16.9  0.3 18.1  0.6 17.4  0.5 17.4  0.6 0.38
BMI, kg/m2 26.7  0.2 26.9  0.3 27.2  0.3 27.7  0.3 0.027
Systolic blood
pressure, mm Hg
120  0.5 121  0.8 123  1.0 124  1.1 <0.001
Diastolic blood
pressure, mm Hg
73  0.4 75  0.7 76  0.8 78  0.8 <0.001
Glucose, mg/dl 89.3  0.5 90.7  0.8 91.4  0.8 95.8  1.4 <0.001
Total cholesterol,
mg/dl
196.8  1.6 200.1  2.9 203.8  2.7 211.3  2.9 <0.001
LDL cholesterol,
mg/dl
129.0  1.4 133.5  2.6 137.7  2.3 141.7  2.6 <0.001
Triglycerides, mg/dl 97.1  2.4 104.1  4.3 106.6  5.1 128.8  6.6 <0.001
Ox-LDL, U/l 55.7  0.9 60.7  1.7 61.9  1.6 64.6  1.6 <0.001
Urinary isoprostanes,
ng/ml
1.16  0.03 1.04  0.05 1.19  0.08 1.28  0.09 0.11
Waist
circumference, cm
93.6  0.5 94.7  0.9 95.5  0.8 97.6  0.9 0.001
HbA1C, % 5.3  0.02 5.4  0.03 5.4  0.03 5.6  0.03 <0.001
Alcohol consumption,
g/day
11.7  0.6 10.7  0.9 12.9  0.9 16.5  1.4 0.001
Women
Plaque Burden (mm3)*
Test for
Trend
p Value
No Plaque
(n ¼ 440)
Tertile 1‡
(n ¼ 52)
Tertile 2‡
(n ¼ 52)
Tertile 3‡
(n ¼ 54)
Age, yrs 44.1  0.2 45.3  0.6 46.1  0.6 48.1  0.6 <0.001
LTL, kb 10.28  0.08 10.09  0.26 10.09  0.21 10.38  0.20 0.74
%LTL<3 kb 16.14  0.28 16.72  0.92 16.75  0.73 15.60  0.69 0.70
BMI, kg/m2 23.78  0.17 24.91  0.51 23.83  0.46 24.73  0.60 0.09
Systolic blood
pressure, mm Hg
108  0.4 111  1.5 112  1.5 115  1.5 <0.001
Diastolic blood
pressure, mm Hg
68  0.4 70  1.3 71  1.1 74  1.2 <0.001
Glucose, mg/dl 84.9  0.4 84.4  1.0 85.1  1.1 85.9  1.3 0.79
Total cholesterol,
mg/dl
192.9  1.4 192.9  4.5 198.0  4.1 209.0  4.2 0.004
LDL cholesterol,
mg/dl
120.2  1.3 124.6  3.6 126.2  3.5 137.0  4.0 <0.001
Triglycerides, mg/dl 70.2  1.3 74.2  4.6 72.6  4.1 74.0  4.5 0.64
Ox-LDL, U/l 47.8  0.7 52.5  2.3 47.4  2.0 53.5  2.5 0.02
Urinary isoprostanes,
ng/ml
0.89  0.03 1.02  0.09 0.78  0.06 1.08  0.14 0.07
Waist
circumference, cm
79.5  0.4 82.1  1.3 81.8  1.2 82.6  1.5 0.037
HbA1C, % 5.2  0.01 5.2  0.04 5.3  0.04 5.4  0.05 0.08
Alcohol consumption,
g/day
4.9  0.3 5.0  0.8 4.6  0.9 3.5  0.7 0.53
*Plaque burden is calculated as a categorical variable (no plaque þ sex speciﬁc tertiles). Results presented as
mean  standard error from analysis of variance test. †Tertile 1: 2.7 to 31.3 mm3; tertile 2: 31.4 to 96.5 mm3;
tertile 3: 96.9 to 1,313 mm3. ‡Tertile 1: 2.1 to 17.5 mm3; tertile 2: 17.7 to 43.5 mm3; tertile 3: 44.2 to 567 mm3.
%LTL<3 kb ¼ percent short telomeres; BMI¼ body mass index; HbA1C ¼ glycosylated hemoglobin; LDL¼ low-
density lipoprotein; LTL ¼ leukocyte telomere length; ox-LDL ¼ oxidized low-density lipoprotein.
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were categorized into tertiles, and CACS was dichot-
omized into <1 and $1 Agatston units. Pearson cor-
relation coefﬁcients were calculated to assess the
associations between telomere parameters and age.
Linear regression lines were ﬁtted to visually assess
the associations between LTL and %LTL<3 kb with
age and cubic regression lines for the associations
between LTL and %LTL<3 kb. The chi-square test and
Student t test were applied to assess differences in
plaque presence and plaque burden between men and
women. The association of other participant charac-
teristics with mean LTL, %LTL<3 kb, or total plaque
burden were assessed with analysis of variance and
linear regression models. Independent associations of
telomere parameters with plaque burden were
assessed with linear regression models adjusted for
other covariates.
Distinct circulating leukocyte subsets have
different mean TLs (26–28). However, because anal-
ysis of our samples revealed no association between
the percentage of different leukocyte subtypes and
plaque burden, this variable was not taken into
account as a confounder in the statistical analysis.
RESULTS
The baseline prevalence of subclinical atherosclerotic
lesions in the 1,459 study participants is summarized
in Table 1. Subclinical atherosclerosis was determined
by vascular ultrasound as the presence of plaques in
the infrarenal aorta, carotid arteries, or iliofemoral
arteries (plaque presence and total plaque burden), or
by CT determination of CACS. Plaques in all territories
and CACS $1 were markedly more prevalent in men
(p < 0.001). Moreover, total plaque burden in partic-
ipants with observed plaques was much higher in
men (p < 0.001). As expected, age in both sexes was
inversely associated with LTL (men: Pearson’s
r ¼ 0.108; p ¼ 0.002; women: Pearson’s r ¼ 0.138;
p ¼ 0.001) (Figure 1A), and directly associated with
%LTL<3 kb (men: Pearson’s r ¼ 0.071; p ¼ 0.039;
women: Pearson’s r ¼ 0.084; p ¼ 0.038) (Figure 1B),
and LTL was signiﬁcantly longer in women than in
men (women: 10.19 kb  1.69 vs. men: 9.96 kb  1.84;
p ¼ 0.019). We also found an inverse association
between LTL and %LTL<3 kb in men (Pearson’s
r ¼ 0.762; p < 0.001) and women (Pearson’s
r ¼ 0.751; p < 0.001) (Figure 1C).
Table 2 shows the stratiﬁcation of CVD risk factors
in the study population by sex and plaque bur-
den. A higher plaque burden was associated with a
worse CVD risk-factor proﬁle, especially among men.
Unadjusted LTL differed signiﬁcantly across theplaque burden categories in men, with the highest
mean LTL value found in men with no plaques
(p-trend ¼ 0.033). LTL showed no signiﬁcant
association with plaque burden among women.
TABLE 3
Factors S
Ris
BMI, kg/m
Waist circu
Overweigh
Glucose, m
Hypertens
Current sm
Yrs smokin
Urine isop
Ox-LDL, U
Total chol
Triglycerid
HbA1C, %
Alcohol in
Ris
BMI, kg/m
Waist circu
Overweigh
Glucose, m
Hypertens
Current sm
Yrs smokin
Urine isop
Ox-LDL, U
Total chol
Triglycerid
HbA1C, %
Alcohol in
*Data are re
CVD ¼ ca
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categories in men or women.
Sex- and age-adjusted associations between
telomere parameters and CVD risk factors are
shown in Table 3. The only direct signiﬁcant asso-
ciations after these adjustments were between
%LTL<3 kb and urinary isoprostanes and serum
ox-LDL in men (p ¼ 0.007 and 0.008, respectively),
and between %LTL<3 kb and serum ox-LDL in
women (p ¼ 0.001).
Associations between telomeres and atheroscle-
rosis burden in the femoral and carotid arteries were
investigated in 3 regression models: unadjusted,
adjusted for age (and sex in nonstratiﬁed models),
and also adjusted for 8 additional CVD risk factors
(Table 4). The analysis considered plaque burden inAssociation Between Telomere Measurements and CVD Risk
tratiﬁed by Sex and Adjusted by Age*
k Factor
Dependent Variable: LTL
Men Women
b Coefﬁcient  SE p Value b coefﬁcient  SE p Value
2 0.032  0.019 0.09 0.021  0.019 0.28
mference, cm 0.008  0.006 0.23 0.004  0.007 0.59
t 0.170  0.140 0.23 0.084  0.151 0.58
g/dl 0.008  0.005 0.15 0.012  0.009 0.21
ion 0.270  0.175 0.12 0.529  0.318 0.09
oker 0.025  0.162 0.88 0.153  0.160 0.34
g 0.010  0.007 0.14 0.002  0.008 0.84
rostanes, ng/dl 0.043  0.074 0.57 0.088  0.098 0.37
/l 0.001  0.003 0.99 0.006  0.004 0.20
esterol, mg/dl 0.003  0.002 0.07 0.002  0.002 0.43
es, mg/dl 0.000  0.001 0.65 0.000  0.002 0.10
0.191  0.146 0.19 0.141  0.219 0.52
take, g/day 0.002  0.005 0.66 0.012  0.011 0.26
k Factor
Dependent Variable: %LTL<3 kb
Men Women
b Coefﬁcient  SE p Value b coefﬁcient  SE p Value
2 0.030  0.065 0.65 0.076  0.066 0.25
mference, cm 0.011  0.023 0.63 0.013  0.025 0.60
t 0.040  0.495 0.94 0.087  0.522 0.87
g/dl 0.024  0.019 0.22 0.013  0.032 0.69
ion 0.110  0.618 0.86 0.883  1.099 0.42
oker 0.130  0.573 0.82 0.053  0.552 0.92
g 0.031  0.023 0.18 0.016  0.027 0.56
rostanes, ng/dl 0.703  0.261 0.007 0.276  0.338 0.41
/l 0.031  0.012 0.008 0.055  0.015 <0.001
esterol, mg/dl 0.009  0.007 0.16 0.007  0.008 0.38
es, mg/dl 0.000  0.004 0.91 0.004  0.008 0.61
0.939  0.513 0.06 0.765  0.755 0.31
take, g/day 0.005  0.017 0.77 0.043  0.038 0.25
gression b coefﬁcients  SE (standard error) in linear regression models.
rdiovascular disease; other abbreviations as in Table 2.these territories individually and in combination
(total plaque burden). In the unadjusted model, LTL
reached statistical signiﬁcance as a determinant of
femoral plaque and total plaque burden in men,
and in the total sample. However, the association
did not hold after adjustment for age and sex
(Model 1) or additional CVD risk factors (Model 2).
For %LTL<3 kb, none of the regression models
showed signiﬁcant associations for men, women, or
the total sample.
DISCUSSION
An association between short LTL and the occurrence
of cardiovascular ischemic events has been described
in several studies (13,14,29); however, information is
still scarce on the relationship between LTL and
subclinical atherosclerosis in subjects free from
established CVD. The short telomere load correlates
with the number of senescent cells (17), suggesting
that an association between CVD and the number
of short telomeres might be better than average LTL
at predicting aging and associated atherosclerosis.
However, previous studies have not investigated
this possible association. Here, we analyzed LTL, as
well as short telomere load (%LTL<3 kb), in a subset
of 1,459 middle-aged CVD-free participants from the
PESA cohort (2,21) (Central Illustration). Our analysis
shows that neither high %LTL<3 kb nor short mean
TL in circulating leukocytes is an independent
determinant of subclinical atherosclerosis after
adjusting for age or other well-known cardiovascular
risk factors.
In 2 of 3 cross-sectional studies performed in
relatively small cohorts (from 129 to 325 subjects),
short LTL showed an association with asymptomatic
atherosclerosis estimated by coronary artery calciﬁ-
cation (30–32). In a 6-year prospective study of
common carotid IMT in 768 participants, telomere
shortening showed an association with increased
subclinical carotid vascular damage and worse
cardiovascular prognosis (33). In a cohort of 800
subjects, short LTL also emerged as a signiﬁcant
and independent predictor for the risk of advanced
atherosclerosis and its complications (myocardial
infarction and stroke), but was not associated
with early atherogenesis (34). Similarly, the large-
scale Asklepios study (2,509 relatively young
volunteers free from established CVD) found no or
only limited independent association between
average LTL and IMT or plaque presence in carotid
or femoral arteries in men and women (15). By
analyzing different vascular territories in 1,459
PESA participants and performing a more extensive
TABLE 4 Association of LTL and %LTL<3 kb With Plaque Burden
Total Sample
(N ¼ 1,349)
Linear
Regression
Model†
LTL (kb) %LTL<3 kb
b Coefﬁcient  SE p Value b Coefﬁcient  SE p Value
Total plaque
burden*
Unadjusted 0.121  0.044 0.006 0.243  0.152 0.11
Model 1 0.031  0.048 0.52 0.049  0.167 0.77
Model 2 0.073  0.050 0.15 0.008  0.173 0.96
Carotid plaque
burden*
Unadjusted 0.021  0.051 0.69 0.071  0.178 0.69
Model 1 0.041  0.052 0.44 0.237  0.181 0.19
Model 2 0.016  0.053 0.76 0.206  0.183 0.26
Femoral plaque
burden*
Unadjusted 0.108  0-047 0.022 0.226  0.163 0.17
Model 1 0.007  0.052 0.89 0.095  0.179 0.59
Model 2 0.048  0.054 0.37 0.060  0.185 0.75
Men
(n ¼ 780)
Linear
Regression
Model†
LTL (kb) %LTL<3 kb
b Coefﬁcient  SE p Value b Coefﬁcient  SE p Value
Total plaque
burden*
Unadjusted 0.116  0.054 0.031 0.159  0.189 0.40
Model 1 0.068  0.057 0.23 0.012  0.201 0.95
Model 2 0.106  0.061 0.08 0.055  0.211 0.79
Carotid plaque
burden*
Unadjusted 0.039  0.064 0.54 0.117  0.227 0.61
Model 1 0.001  0.066 0.99 0.220  0.232 0.34
Model 2 0.023  0.068 0.74 0.190  0.238 0.43
Femoral plaque
burden*
Unadjusted 0.111  0.059 0.06 0.218  0.207 0.29
Model 1 0.053  0.063 0.40 0.053  0.221 0.81
Model 2 0.092  0.067 0.17 0.087  0.233 0.71
Women
(n ¼ 569)
Linear
Regression
Model†
LTL (kb) %LTL<3 kb
b Coefﬁcient  SE p Value b Coefﬁcient  SE p Value
Total plaque
burden*
Unadjusted 0.030  0.083 0.08 0.061  0.282 0.83
Model 1 0.055  0.086 0.09 0.114  0.294 0.70
Model 2 0.008  0.090 0.09 0.111  0.308 0.72
Carotid plaque
burden*
Unadjusted 0.016  0.080 0.08 0.104  0.272 0.70
Model 1 0.073  0.081 0.08 0.002  0.278 0.99
Model 2 0.060  0.083 0.08 0.055  0.284 0.85
Femoral plaque
burden*
Unadjusted 0.004  0.097 0.10 0.182  0.331 0.58
Model 1 0.099  0.100 0.10 0.388  0.343 0.26
Model 2 0.032  0.105 0.11 0.336  0.359 0.35
*Plaque burden is calculated as a categorical variable (0 value þ sex-speciﬁc tertiles). †Linear regression models:
Unadjusted ¼ no adjustments; Model 1 ¼ age (and sex in nonstratiﬁed models); Model 2 ¼ model 1 þ systolic
blood pressure, diastolic blood pressure, hypertension diagnosis, fasting glucose, total cholesterol, smoking
status, HbA1C, ox-LDL, urine isoprostanes, and alcohol intake.
Abbreviations as in Table 2.
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burden, which included not only the presence/
absence of plaques, but also the continuous variable
“plaque volume,” our studies reinforce the notion
that average LTL is not associated with subclinical
atherosclerosis. In addition, we show for the ﬁrst
time that the abundance of short telomeres in leu-
kocytes is not an independent determinant of sub-
clinical atherosclerosis in carotid or femoral arteries.
It would be important, however, to carry out lon-
gitudinal studies with the same participants
analyzed herein to ascertain whether telomere
attrition over time is associated with cardiovascular
ischemic events. As expected, men in our cohort
had a higher prevalence of subclinical atheroscle-
rosis than women. This might explain the signiﬁ-
cant association of total plaque burden with LTL in
men, but not in women, in the unadjusted model.
Indeed, the overall young age of the study popula-
tion might help to explain the lack of association
between LTL and plaque burden, especially for
women, who generally have a lower atherosclerosis
burden than men of the same age.
Telomere dysfunction induces metabolic and
mitochondrial compromise (35), and increased
burden of oxidative stress can accelerate LTL attri-
tion (12,29). Consistent with the results of multi-
variate regression analyses showing that femoral
artery plaques are independently related to serum
ox-LDL (36), we found signiﬁcantly higher serum
ox-LDL concentrations among participants with a
higher plaque burden. Although we did not observe
signiﬁcant association between mean LTL and serum
ox-LDL, interestingly, the %LTL<3 kb was signiﬁ-
cantly higher in men and women with higher serum
ox-LDL levels. These results suggest that accumu-
lation of short telomeres correlates with abnormal
lipid accumulation in blood; therefore, longitudinal
follow up of PESA participants will be of high
interest.
STUDY LIMITATIONS. First, our sample represents a
homogeneous middle-aged and sociodemographic-
speciﬁc population, and thus might not be represen-
tative of the general population; different results
might be obtained in studies carried out with
participants who are older (and thus have a
larger extent of subclinical atherosclerosis) or who
have different ethnic or demographic proﬁles
(13,14,29). Second, our results are limited by the
cross-sectional nature of the study. Prospective or
longitudinal studies of large samples are clearly
needed to establish with conﬁdence whether there is
an association between telomere parameters andthe progression of subclinical atherosclerosis, and
whether such an association could help identify
subjects at high risk of developing CVD before
symptoms appear (e.g., increased atherosclerosis
progression, and risk of myocardial infarction and
stroke in subjects with higher rates of LTL attrition
and/or more accumulation of short telomeres over
CENTRAL ILLUSTRATION Telomere Length and Subclinical Atherosclerosis: Design and Objectives
Fernández-Alvira, J.M. et al. J Am Coll Cardiol. 2016;67(21):2467–76.
In a cross-sectional study, different vascular territories were analyzed by 2-dimensional and 3-dimensional ultrasound to quantify subclinical atherosclerosis burden
and examine possible associations with mean telomere length and short telomere load in peripheral blood leukocytes examined by high-throughput quantitative
ﬂuorescence in situ hybridization.
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2474time). Indeed, telomere shortening and accu-
mulation of short telomeres over time has been pro-
posed to be predictive of mortality in birds and
mammals (37–39).
CONCLUSIONS
The results of our cross-sectional study of middle-
aged men and women free from established CVD
show that short mean telomere length and the
amount of short telomeres (<3 kb) in leukocytes are
not signiﬁcant independent determinants of sub-
clinical atherosclerosis burden. Future longitudinal
studies are warranted to determine whether variation
in telomere length over time is a predictor ofsubclinical atherosclerosis progression or the occur-
rence of cardiovascular ischemic events.
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